| Literature DB >> 30489345 |
Noriko Inada1, Jun Shoji, Satoru Yamagami.
Abstract
This study is a retrospectively recruited case series. We report three infants with acute conjunctivitis induced by β-lactamase-positive, ampicillin/clavulanic acid-resistant strains of Haemophilus influenzae (BLPACR). Patients with BLPACR-positive cultures were recruited from among 5,107 patients with inflammatory diseases of the ocular surface who underwent examinations, including bacterial culturing of conjunctival sac or corneal scrapings, between 2000 and 2015. Three BLPACR-positive patients were recruited, including a 10-month-old boy, a 4-month-old girl, and a 7-month-old girl. All three demonstrated BLPACR conjunctivitis. The clinical findings in these patients included fever, mucopurulent discharge, lid swelling, and conjunctival hyperemia. Samples of conjunctival swabs were obtained from all three infants, and BLPACR was isolated from all these conjunctival swabs. Antimicrobial susceptibility testing showed sensitivity to levofloxacin and resistance to ampicillin, cefaclor, and clarithromycin. We conclude that in infantile BLPACR conjunctivitis, simultaneous investigation for the determination of causative organism and antibiotic susceptibility testing are crucial aspects of the medical treatment.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30489345 PMCID: PMC6493690 DOI: 10.1097/ICL.0000000000000556
Source DB: PubMed Journal: Eye Contact Lens ISSN: 1542-2321 Impact factor: 2.018
FIG. 1.Palpebral and bulbal conjunctiva photographs for case 1. Severe hyperemia was observed in the palpebral (A) and bulbal (B) conjunctiva, and subconjunctival hemorrhage in the bulbal conjunctiva.
Clinical Characteristics of Three Infants With BLPACR Conjunctivitis
FIG. 2.Clinical approach for case 1. The patient was given antibiotic therapy by instillation of cefmenoxim four times daily for 4 days, and levofloxacin four times daily for another 5 days, in addition to administration of cefdinir at 11 mg/kg/day for 5 days. +, mild; ++, moderate; +++, severe. CMX, cefmenoxime; LVFX, levofloxacin; CFDN, cefdinir; PO, orally.
Results of Antimicrobial Susceptibility Testing